Cargando…

Coexpression of HHLA2 and PD-L1 on Tumor Cells Independently Predicts the Survival of Spinal Chordoma Patients

BACKGROUND: Immunotherapy only achieves efficacy in some cancer patients, and less is known about other immune checkpoint molecules in chordoma. Here, we aimed to determine the expression of PD-L1, HHLA2, B7H3, IDO-1 and Galectin-9 in spinal chordoma and evaluated their association with tumor infilt...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xia, Chao, Huang, Wei, Chen, Yun-Liang, Fu, Hai-Bin, Tang, Ming, Zhang, Tao-Lan, Li, Jing, Lv, Guo-Hua, Yan, Yi-Guo, Ouyang, Zhi-Hua, Yao, Nvzhao, Wang, Cheng, Zou, Ming-Xiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8824251/ https://www.ncbi.nlm.nih.gov/pubmed/35145510 http://dx.doi.org/10.3389/fimmu.2021.797407

Ejemplares similares

Corrigendum: Coexpression of HHLA2 and PD-L1 on tumor cells independently predicts the survival of spinal chordoma patients
por: Xia, Chao, et al.
Publicado: (2023)

HHLA2 predicts improved prognosis of anti-PD-1/PD-L1 immunotherapy in patients with melanoma
por: Huang, Fu-xue, et al.
Publicado: (2022)

Development and Validation of a 6-miRNA Prognostic Signature in Spinal Chordoma
por: Huang, Wei, et al.
Publicado: (2020)

Comprehensive Analysis of HHLA2 as a Prognostic Biomarker and Its Association With Immune Infiltrates in Hepatocellular Carcinoma
por: Ding, Lin, et al.
Publicado: (2022)

A four‐factor immune risk score signature predicts the clinical outcome of patients with spinal chordoma
por: Zou, Ming‐Xiang, et al.
Publicado: (2020)

Clinicopathological and Prognostic Characteristics in Dedifferentiated/Poorly Differentiated Chordomas: A Pooled Analysis of Individual Patient Data From 58 Studies and Comparison With Conventional Chordomas
por: Liu, Fu-Sheng, et al.
Publicado: (2021)

KIR3DL3-HHLA2 and TMIGD2-HHLA2 pathways: The dual role of HHLA2 in immune responses and its potential therapeutic approach for cancer immunotherapy
por: Li, Yang, et al.
Publicado: (2022)

Prognostic Significance of Potential Immune Checkpoint Member HHLA2 in Human Tumors: A Comprehensive Analysis
por: Wang, Ben, et al.
Publicado: (2019)

Novel immune scoring dynamic nomograms based on B7-H3, B7-H4, and HHLA2: Potential prediction in survival and immunotherapeutic efficacy for gallbladder cancer
por: Lv, Chao, et al.
Publicado: (2022)

HHLA2 and PD-L1 co-expression predicts poor prognosis in patients with clear cell renal cell carcinoma
por: Zhou, Qiang-Hua, et al.
Publicado: (2020)

HHLA2 Expression is Associated with Poor Survival in Patients with Hepatocellular Carcinoma
por: Xu, Yituo, et al.
Publicado: (2021)

The role of tumor immune microenvironment in chordoma: promising immunotherapy strategies
por: Xu, Jiuhui, et al.
Publicado: (2023)

HHLA2 predicts better survival and exhibits inhibited proliferation in epithelial ovarian cancer
por: Xu, Guocai, et al.
Publicado: (2021)

Increased coexpression of PD-L1 and TIM3/TIGIT is associated with poor overall survival of patients with esophageal squamous cell carcinoma
por: Wang, Peipei, et al.
Publicado: (2021)

HHLA2 in intrahepatic cholangiocarcinoma: an immune checkpoint with prognostic significance and wider expression compared with PD-L1
por: Jing, Chu-Yu, et al.
Publicado: (2019)

Immune Myocarditis Overlapping With Myasthenia Gravis Due to Anti-PD-1 Treatment for a Chordoma Patient: A Case Report and Literature Review
por: Liang, Shujing, et al.
Publicado: (2021)

Regulation of HHLA2 expression in kidney cancer and myeloid cells
por: Shigemura, Tomonari, et al.
Publicado: (2023)

CMTM6 and PD-L1 coexpression is associated with an active immune microenvironment and a favorable prognosis in colorectal cancer
por: Peng, Qi-Hua, et al.
Publicado: (2021)

Identification of Key Genes in Severe Burns by Using Weighted Gene Coexpression Network Analysis
por: Guo, ZhiHui, et al.
Publicado: (2022)

Clinical Significance of the HHLA2 Protein in Hepatocellular Carcinoma and the Tumor Microenvironment
por: Luo, Min, et al.
Publicado: (2021)

HHLA2, a member of the B7 family, is expressed in human osteosarcoma and is associated with metastases and worse survival
por: Koirala, Pratistha, et al.
Publicado: (2016)

Overexpression of HHLA2, a member of the B7 family, is associated with worse survival in human colorectal carcinoma
por: Zhu, Ziwen, et al.
Publicado: (2018)

Overexpression of HHLA2 in human clear cell renal cell carcinoma is significantly associated with poor survival of the patients
por: Chen, Lujun, et al.
Publicado: (2019)

Correction: HHLA2 and PD-L1 co-expression predicts poor prognosis in patients with clear cell renal cell carcinoma
Publicado: (2020)

Chordoma recruits and polarizes tumor-associated macrophages via secreting CCL5 to promote malignant progression
por: Xu, Jiuhui, et al.
Publicado: (2023)

Whole genome sequencing of skull-base chordoma reveals genomic alterations associated with recurrence and chordoma-specific survival
por: Bai, Jiwei, et al.
Publicado: (2021)

CTLA-4 Synergizes With PD1/PD-L1 in the Inhibitory Tumor Microenvironment of Intrahepatic Cholangiocarcinoma
por: Guo, Xiao-Jun, et al.
Publicado: (2021)

Combination of Anti-PD-1 Antibody, Anlotinib and Pegaspargase “Sandwich” With Radiotherapy in Localized Natural Killer/T Cell Lymphoma
por: Sun, Peng, et al.
Publicado: (2022)

Clinical Significance of the HHLA2 Protein in Hepatocellular Carcinoma and the Tumor Microenvironment [Corrigendum]
Publicado: (2021)

Overexpression and Role of HHLA2, a Novel Immune Checkpoint, in Colorectal Cancer
por: Kula, Agnieszka, et al.
Publicado: (2023)

Response: Commentary: Single-Cell Sequencing Analysis and Weighted CoExpression Network Analysis Based on Public Databases Identified That TNC Is a Novel Biomarker for Keloid
por: Xie, Jiaheng, et al.
Publicado: (2022)

Association of PD-L1 and HIF-1α Coexpression with Poor Prognosis in Hepatocellular Carcinoma
por: Dai, Xiaomeng, et al.
Publicado: (2018)

Computer Navigation-aided Resection of Sacral Chordomas
por: Yang, Yong-Kun, et al.
Publicado: (2016)

Identification of Biomarkers Associated With CD4(+) T-Cell Infiltration With Gene Coexpression Network in Dermatomyositis
por: Huang, Peng, et al.
Publicado: (2022)

Thoracic dumbbell spinal chordoma mimicking a schwannoma
por: Costanzo, Roberta, et al.
Publicado: (2021)

Chordoma of petrosal mastoid region: A case report
por: Hua, Jian-Jun, et al.
Publicado: (2022)

Biological Characteristics and Clinical Significance of Soluble PD-1/PD-L1 and Exosomal PD-L1 in Cancer
por: Niu, Mengke, et al.
Publicado: (2022)

Metastatic skull base chordoma: A systematic review
por: Young, Kurtis, et al.
Publicado: (2022)

HHLA2 is a novel prognostic predictor and potential therapeutic target in malignant glioma
por: Qi, Yangzhi, et al.
Publicado: (2019)

HHLA2 is a novel prognostic predictor and potential therapeutic target in malignant glioma
por: Qi, Yangzhi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_hkr93udste36fusrdgjv3l2she